MP73-03 PD-L1 EXPRESSION IN XP11.2 TRANSLOCATION RENAL CELL CARCINOMA: INDICATOR OF TUMOR AGGRESSIVENESS

Abstract

You have accessJournal of UrologyKidney Cancer: Basic Research & Pathophysiology III1 Apr 2017MP73-03 PD-L1 EXPRESSION IN XP11.2 TRANSLOCATION RENAL CELL CARCINOMA: INDICATOR OF TUMOR AGGRESSIVENESS Yuan-Yuan Qu, Kun Chang, Bo Dai, Yao Zhu, Hai-Liang Zhang, and Ding-Wei Ye Yuan-Yuan QuYuan-Yuan Qu More articles by this author , Kun ChangKun Chang More articles by this author , Bo DaiBo Dai More articles by this author , Yao ZhuYao Zhu More articles by this author , Hai-Liang ZhangHai-Liang Zhang More articles by this author , and Ding-Wei YeDing-Wei Ye More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.3348AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Programmed death ligand-1 (PD-L1), as a promising anti-tumor target, has proved its significant clinical value in many malignancies. However, the expression of PD-L1 in Xp11.2 translocation renal cell carcinoma (Xp11.2 RCC) and association with clinical outcomes remains unclear. This study amid to investigate the expression of PD-L1 in Xp11.2 RCC and to assess its prognostic value. METHODS Immunohistochemistry was conducted on formalin-fixed paraffin-embedded specimens from 36 adult Xp11.2 RCC patients who were histologically confirmed by FISH analysis. Students's t-test and Chi-square test were used to evaluate the relationship between PD-L1 expression and clinicopathological parameters. Cox regression models were used to evaluate the prognostic value of all parameters. RESULTS Among 36 assessed Xp11.2 RCC patients, 9 (25.0%) patients showed high expression of PD-L1 and 27 (75.0%) patients showed low PD-L1 expression. High PD-L1 expression was correlated with the presence of advanced tumor stage (P=0.001), regional lymph node metastasis (P<0.001) and distant metastasis (P<0.001). In the multivariate analysis, N stage (HR: 4.316, P = 0.032), M stage (HR: 16.561, P = 0.009) and high PD-L1 expression (HR: 4.236, P = 0.007) were independent prognostic factors of PFS. Moreover, high PD-L1 expression (HR: 6.479, P = 0.006), along with distant metastasis (HR: 9.215, P = 0.016), was independent prognostic factors after adjusting for covariates. CONCLUSIONS High PD-L1 expression is independently associated with tumor progression and predictive of adverse prognosis for Xp11.2 RCC patients. Importantly, our findings may provide a basis for the use of immunotherapy targeting the PD-1/PD-L1 pathway as a potential novel treatment for Xp11.2 RCC patients. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e964 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Yuan-Yuan Qu More articles by this author Kun Chang More articles by this author Bo Dai More articles by this author Yao Zhu More articles by this author Hai-Liang Zhang More articles by this author Ding-Wei Ye More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...